Search
5 articles for “HDAC inhibitors”
-
In Silico Assessment of Drug like Properties of Some Thiadiazole and Oxadiazole Derivatives as HDAC Inhibitors
Abstract: Purpose: To investigate in silico the drug-like properties of some thiadiazole and oxadiazole derivatives as HDAC inhibitors. Methods: We used Chemdraw Ultra 11.0 to redraw all chemical structures. Furthermore, some applications, such as Bio-Loom for Windows - version 1.5, Molinspiration Property Calculator, and ACD/I-LAB, were used to forecast the drug-like properties of thiadiazole and oxadiazole derivatives, including relative molecular mass (MW), partition coefficient log P (cLog P), number of hydrogen …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 9, Issue 2, 2022 · pp. 1–13 Read article
-
HDAC and HDAC Inhibitors: Implication in Different Pathological Ailments
Abstract: Histone deacetylases (HDAC) and its inhibitors have been found implicated in various diseased conditions. HDACs regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. They have also been found to regulate the post translational modifications through deacetylation of proteins, and hence are involved in many pathophysiological conditions. Till date, USFDA has approved vorinostat, romidepsin, panobinostat, and belinostat as HDAC inhibitors for the treatment of cancer. Considering their wide …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 5, Issue 3, 2018 · pp. 35–40 Read article
-
In Silico Study of Histone Deacetylase Inhibitor as Anticancer Agents
Abstract: The clinical selective histone deacetylase inhibitor vorinostat is most commonly used for the treatment of lymphoma and solid tumor and has been preventing lives worldwide. Vorinostat is used in both treatment and prevention of lymphoma and other tumors. Based on these for current study some vorinostat derivatives with thiadiazole moiety containing derivatives have been designed for in silico study. For present work, the already selected study was against histone human …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 6, Issue 2, 2019 · pp. 6–23 Read article
-
Pharmacoepigenomics of Replication Timing: How Anti- Cancer Drugs Reshape Chromatin Domains and Mutational Landscapes.
Abstract: DNA replication timing serves as a fundamental epigenetic feature that organizes genome function during the cell cycle (3), while anti-cancer drugs profoundly alter this process to disrupt tumor growth(4). These agents target chromatin architecture, shifting replication domains and reshaping mutational patterns critical for cancer evolution (1,5). DNA replication timing (RT) domains serve as dynamic epigenetic organizers, partitioning the genome into early- and late-replicating regions that correlate with chromatin states, gene …
Published in International Journal of Molecular Biotechnological Research · Vol. 4, Issue 1, 2026 · pp. 41–50 Read article
-
REVIEW OF PHARMACOEPIGENETICS: BRIDGING EPIGENETICS AND PERSONALIZED MEDICINE
Abstract: Pharmacoepigenetics is an emerging field that explores how alterations in gene expression, independent of DNA sequence changes, influence individual responses to drugs. Unlike pharmacogenetics, which focuses primarily on genetic variation, pharmacoepigenetics integrates genetic, environmental, and lifestyle factors to explain interindividual differences in drug efficacy, toxicity, and resistance. Key epigenetic mechanisms including DNA methylation, histone modifications, non-coding RNAs, and RNA methylation play critical roles in regulating drug metabolism and therapeutic outcomes. …
Published in International Journal of Molecular Biotechnological Research · Vol. 4, Issue 1, 2026 · pp. 33–40 Read article